GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Basilea Pharmaceutica Ltd (LTS:0QNA) » Definitions » Total Inventories

Basilea Pharmaceutica (LTS:0QNA) Total Inventories : CHF26.4 Mil (As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Basilea Pharmaceutica Total Inventories?

Basilea Pharmaceutica's total inventories for the quarter that ended in Dec. 2023 was CHF26.4 Mil. Basilea Pharmaceutica's average total inventories from the quarter that ended in Jun. 2023 to the quarter that ended in Dec. 2023 was CHF26.0 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Basilea Pharmaceutica's Net-Net Working Capital per share for the quarter that ended in Dec. 2023 was CHF-7.44.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Basilea Pharmaceutica's Days Inventory for the six months ended in Dec. 2023 was 282.73.

Inventory Turnover measures how fast the company turns over its inventory within a year. Basilea Pharmaceutica's Inventory Turnover for the quarter that ended in Dec. 2023 was 0.65.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Basilea Pharmaceutica's Inventory-to-Revenue for the quarter that ended in Dec. 2023 was 0.36.


Basilea Pharmaceutica Total Inventories Historical Data

The historical data trend for Basilea Pharmaceutica's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Basilea Pharmaceutica Total Inventories Chart

Basilea Pharmaceutica Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Inventories
Get a 7-Day Free Trial Premium Member Only Premium Member Only 18.57 21.19 22.78 24.24 26.41

Basilea Pharmaceutica Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Total Inventories Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 22.78 24.75 24.24 25.64 26.41

Basilea Pharmaceutica Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.


Basilea Pharmaceutica  (LTS:0QNA) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Basilea Pharmaceutica's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2023 is

Net-Net Working Capital Per Share (Q: Dec. 2023 )
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(59.9+0.75 * 27.891+0.5 * 26.41-183.291
-0-0)/12.0017
=-7.44

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Basilea Pharmaceutica's Days Inventory for the six months ended in Dec. 2023 is calculated as:

Days Inventory=Average Total Inventories (Q: Dec. 2023 )/Cost of Goods Sold (Q: Dec. 2023 )*Days in Period
=26.024/16.798*365 / 2
=282.73

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Basilea Pharmaceutica's Inventory Turnover for the quarter that ended in Dec. 2023 is calculated as

Inventory Turnover=Cost of Goods Sold (Q: Dec. 2023 ) / Average Total Inventories (Q: Dec. 2023 )
=16.798 / 26.024
=0.65

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Basilea Pharmaceutica's Inventory to Revenue for the quarter that ended in Dec. 2023 is calculated as

Inventory-to-Revenue=Average Total Inventories (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=26.024 / 72.729
=0.36

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.


Basilea Pharmaceutica Total Inventories Related Terms

Thank you for viewing the detailed overview of Basilea Pharmaceutica's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.


Basilea Pharmaceutica (LTS:0QNA) Business Description

Traded in Other Exchanges
Address
Switzerland Innovation Park, Basel Area, Main Campus, Near Basel, Allschwil, CHE, 4058
Basilea Pharmaceutica Ltd is a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing drugs to meet the needs of patients with severe bacterial and fungal infections. The Company has operating subsidiaries in the United Kingdom and Germany. Geographically company derives revenue from Japan, Ireland, Republic of Korea, USA, Uruguay, Sweden, Canada, Jordan, Switzerland and Other countries.

Basilea Pharmaceutica (LTS:0QNA) Headlines

No Headlines